Drugs

Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer

Photo taken from Matthew Goetz/LinkedIn

Apr 29, 2024, 14:18

Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer

Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:

“An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with Abemacicib:

Is the benefit of Abemacicib compromised in those that require dose reductions?

A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy.

Clinicians should utilize dose modifications when necessary to maximize adherence.”

Matthew Goetz

Additional information.
Source: Matthew Goetz/LinkedIn

Abemacicib Ashwin Shahir Breast Cancer cancer Hope S. Rugo Irfan Cicin Jens Huober Joyce O'Shaughnessy Laura Testa Matthew Goetz Mayo Clinic Miguel Martin monarchE Nadia Harbeck OncoDaily Oncology Priya Rastogi Ran Wei Sara M. Tolaney Stephen R. D. Johnston Valentina Guarneri Valérie André

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth